We are live on ! Find out more
OMED

OncoMed Pharmaceuticals, Inc.
OMED

Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

68 hedge funds and large institutions have $179M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more call options, than puts

Call options by funds: $200K | Put options by funds: $85K

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

26% more capital invested

Capital invested by funds: $143M → $179M (+$36.5M)

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

10% more funds holding

Funds holding: 62 → 68 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
20
Reduced
16
Closed
9
Calls
$200K
Puts
$85K
Net Calls
+$115K
Net Calls Change
-$1.43M

Top Buyers

Rank Fund Capital Flow
1
AC
Apex Capital
California
+$7.07M
2
Norges Bank
Norges Bank
Norway
+$3.74M
3
ICM
IronBridge Capital Management
Illinois
+$3.02M
4
BI
BVF Inc
California
+$1.78M
5
QI
QS Investors
New York
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
CIP
Convergence Investment Partners
Florida
-$2.12M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$1.97M
3
SFM
Sphera Funds Management
Israel
-$1.84M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.68M
5
VAM
Visium Asset Management
New York
-$1.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$1.15M – – –
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$990K -$1.68M -82,253 -64%
TAM
28
Tocqueville Asset Management
New York
$943K +$20.5K +1,000 +2%
BIM
29
BlackRock Investment Management
Delaware
$795K -$8.52K -416 -1%
SO
30
STRS Ohio
Ohio
$731K +$46.2K +2,253 +7%
Charles Schwab
31
Charles Schwab
California
$644K +$16.2K +793 +3%
GT
32
Glenmede Trust
Pennsylvania
$624K – – –
BA
33
BlackRock Advisors
Delaware
$548K +$408K +19,924 +379%
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$508K +$2.05K +100 +0.4%
ProShare Advisors
35
ProShare Advisors
Maryland
$489K +$43.3K +2,114 +10%
AP
36
AlpInvest Partners
Netherlands
$489K +$460K +22,450 New
BC
37
Birchview Capital
Vermont
$489K +$461K +22,489 New
CS
38
Credit Suisse
Switzerland
$451K +$160K +7,822 +61%
Renaissance Technologies
39
Renaissance Technologies
New York
$450K -$398K -19,435 -48%
Citigroup
40
Citigroup
New York
$435K +$219K +10,670 +115%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$406K +$382K +18,668 New
TA
42
Teachers Advisors
New York
$383K – – –
SIM
43
Spark Investment Management
New York
$382K +$361K +17,600 New
BAM
44
Brave Asset Management
New Jersey
$378K +$248K +12,100 +230%
Bank of Montreal
45
Bank of Montreal
Ontario, Canada
$330K +$85.8K +4,191 +38%
HCM
46
Hodges Capital Management
Texas
$326K – – –
AQR Capital Management
47
AQR Capital Management
Connecticut
$263K +$248K +12,100 New
MLICM
48
Metropolitan Life Insurance Company (MetLife)
New York
$224K – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$223K +$210K +10,230 New
AIG
50
American International Group
New York
$219K -$17.4K -850 -8%
1
2
3 4

OMED Hedge Fund Activity: Q4 2014 in Review

68 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2014, worth a combined $179M — up 26% from $143M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new OMED positions and 9 closed out — a net gain of 9 holders — while 20 added to existing stakes and 16 trimmed.

The largest buyer was Apex Capital, opening a new position worth an estimated $7.07M. The largest seller was Convergence Investment Partners, exiting entirely with an estimated $2.12M sold.

  • 68 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2014, up from 62 in Q3 2014.
  • Funds reported $179M of OncoMed Pharmaceuticals, Inc. stock for Q4 2014, up 26% quarter-over-quarter.
  • 18 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2014 and 9 closed out, a net change of +9 holders.
  • The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2014 was Apex Capital, an estimated $7.07M added.
  • The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2014 was Convergence Investment Partners, an estimated $2.12M sold.

Based on aggregated 13F filings for Q4 2014.